Abstract:Germline mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 have been linked to the development of breast cancer, ovarian cancer, and other malignancies. Recent studies suggest that the BRCA1 and BRCA2 gene products may function in the sensing and/or repair of DNA damage. To investigate this possibility, we determined the effects of various DNA-damaging agents and other cytotoxic agents on the mRNA levels of BRCA1 and BRCA2 in the MCF-7 and other human breast cancer cell lines. We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels. Decreased levels of BRCA1 and BRCA2 mRNAs were observed within 6–12 h after treatment with adriamycin and persisted for at least 72 h. Adriamycin also induced decreases in BRCA1 protein levels; but these decreases required several days. U.V. radiation induced dose-dependent down-regulation of BRCA1 and BRCA2 mRNAs, with significant decreases in both mRNAs at doses as low as 2.5 J/m2, a dose that yielded very little cytotoxicity. Adriamycin-induced down-regulation of BRCA1 and BRCA2 mRNAs was first observed at doses that yielded relatively little cytotoxicity and little or no apoptotic DNA fragmentation. Adriamycin and U.V. radiation induced distinct dose- and time-dependent alterations in the cell cycle distribution; but these alterations did not correlate well with corresponding changes in BRCA1 and BRCA2 mRNA levels. However, the adriamycin-induced reduction in BRCA1 and BRCA2 mRNA levels was correlated with p53 functional status. MCF-7 cells transfected with a dominant negative mutant p53 (143 val→ala) required at least tenfold higher doses of adriamycin to down-regulate BRCA1 and BRCA2 mRNAs than did parental MCF-7 cells or control-transfected MCF-7 clones. These results suggest that BRCA1 and BRCA2 may play roles in the cellular response to DNA-damaging agents and that there may be a p53-sensitive component to the regulation of BRCA1 and BRCA2 mRNA expression.

Data from BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress

Supplementary Table 1 from BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress

BRCA1 is an Essential Regulator of Heart Function and Survival Following Myocardial Infarction

Molecular Functions of BRCA1 in the DNA Damage Response

BRCA1 As a Potential Human Prostate Tumor Suppressor: Modulation of Proliferation, Damage Responses and Expression of Cell Regulatory Proteins

Regulation of BRCA1 and BRCA2 Expression in Human Breast Cancer Cells by DNA-damaging Agents.

Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.

BRCA1 regulates gene expression for orderly mitotic progression.

BRCA1 Regulates Human Mammary Stem/progenitor Cell Fate

BRCA1 regulation of transcription

Breast cancer susceptibility gene 1 regulates oxidative damage via nuclear factor erythroid 2-related factor 2 in oral cancer cells

Abstract #4440: BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells

Data from Absence of the Full-Length Breast Cancer–Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members

Brca1 Deficiency Induces Protective Autophagy To Mitigate Stress And Provides A Mechanism For Brca1 Haploinsufficiency In Tumorigenesis

Absence Of Full-Length Brca1 Sensitizes Mice To Oxidative Stress And Carcinogen-Induced Tumorigenesis In The Esophagus And Forestomach

Brca1 Regulates Gadd45 Through Its Interactions With The Oct-1 And Caat Motifs

Deficiency of Human BRCA2 Leads to Impaired Homologous Recombination but Maintains Normal Nonhomologous End Joining

Negative Regulation Of Akt Activation By Brca1

Systematic Screening Reveals a Role for BRCA1 in the Response to Transcription-Associated DNA Damage.

BRCA1 in Hormonal Carcinogenesis: Basic and Clinical Research

BRCA1 inhibition of telomerase activity in cultured cells.